Livforsakringsbolaget Skandia Omsesidigt Trims Position in Eli Lilly and Company $LLY

Key Points

• Livforsakringsbolaget Skandia Omsesidigt trimmed its Eli Lilly stake by 4.3% in Q3, selling 1,200 shares to hold 26,506 shares worth about $20.21 million, which is ~0.8% of its portfolio and its 22nd largest position.
• Eli Lilly reported strong quarterly results—EPS $7.54 vs. $7.48 expected and revenue $19.29B (up 42.6% YoY)—and set FY2026 guidance of 33.50–35.00 EPS, while sell‑side forecasts average ~23.48 EPS for the current fiscal year.
• The stock has fallen (~down 5.9%) amid mixed analyst actions and headlines: several firms raised targets (consensus target ~$1,221.44), but HSBC downgraded the name and competition/valuation concerns—notably a new GLP‑1 oral pill—have pressured shares.

Livforsakringsbolaget Skandia Omsesidigt decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 4.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 26,506 shares of the company's stock after selling 1,200 shares during the period. Eli Lilly and Company makes up approximately 0.8% of Livforsakringsbolaget Skandia Omsesidigt's holdings, making the stock its 22nd largest position. Livforsakringsbolaget Skandia Omsesidigt's holdings in Eli Lilly and Company were worth $20,207,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. 10Elms LLP raised its stake in Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company's stock valued at $31,000 after acquiring an additional 10 shares during the last quarter. Bridgewater Advisors Inc. grew its stake in shares of Eli Lilly and Company by 0.3% in the 3rd quarter. Bridgewater Advisors Inc. now owns 3,955 shares of the company's stock valued at $3,018,000 after purchasing an additional 11 shares during the last quarter. Manske Wealth Management grew its stake in shares of Eli Lilly and Company by 2.5% in the 3rd quarter. Manske Wealth Management now owns 448 shares of the company's stock valued at $342,000 after purchasing an additional 11 shares during the last quarter. Guardian Partners Inc. grew its stake in shares of Eli Lilly and Company by 0.3% in the 3rd quarter. Guardian Partners Inc. now owns 4,000 shares of the company's stock valued at $3,302,000 after purchasing an additional 12 shares during the last quarter. Finally, FSA Wealth Management LLC increased its holdings in shares of Eli Lilly and Company by 4.0% in the third quarter. FSA Wealth Management LLC now owns 309 shares of the company's stock valued at $236,000 after purchasing an additional 12 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Down 5.9%

Eli Lilly and Company stock opened at $931.03 on Wednesday. The stock's 50 day moving average price is $1,033.54 and its 200 day moving average price is $955.52. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The company has a market cap of $879.65 billion, a PE ratio of 40.57, a price-to-earnings-growth ratio of 1.15 and a beta of 0.40. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm had revenue of $19.29 billion during the quarter, compared to analysts' expectations of $17.85 billion. During the same quarter in the prior year, the business posted $5.32 earnings per share. Eli Lilly and Company's revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Positive pediatric Phase‑3 results for EBGLYSS (lebrikizumab) expand Lilly’s immunology franchise and reduce execution risk on non‑GLP pipeline growth—a clear constructive catalyst for longer‑term revenue diversification. Lilly EBGLYSS Phase 3 Pediatric Results
• Positive Sentiment: Several Wall Street firms remain bullish—some raising targets and highlighting Zepbound/Mounjaro momentum and distribution initiatives (e.g., Employer Connect)—which supports medium‑term sales and margin expectations. Wall Street Firms Turn Bullish on Eli Lilly
• Neutral Sentiment: Disclosure that a member of Congress purchased LLY shares is a data point that can increase watchlist activity but is not a fresh fundamental catalyst. Members of Congress Bought These 5 Stocks—Should You?
• Negative Sentiment: HSBC downgraded LLY to “reduce” (cutting its price target to $850) citing pricing pressure, rising competition, and what it sees as overstated obesity‑market growth—this downgrade triggered selling and repricing of growth expectations. Eli Lilly Analyst Flags Overhyped Obesity Drug Expectations
• Negative Sentiment: Competitive threats intensified after reports of a new GLP‑1 oral pill showing strong weight‑loss data and commentary about Novo Nordisk rivalry; investors are re‑assessing Lilly’s pricing power and market share durability. Structure Weight‑Loss Pill Results Rival Novo, Lilly Treatments
• Negative Sentiment: Market writeups highlight valuation risk: with high multiples already priced for continued GLP‑1 growth, any downgrade or slower uptake triggers outsized downside as investors rotate away from stretched growth names. Why Eli Lilly Stock Just Dropped

Analysts Set New Price Targets

LLY has been the subject of several analyst reports. Jefferies Financial Group set a $1,300.00 price target on Eli Lilly and Company and gave the stock a "buy" rating in a research note on Friday. Wolfe Research lifted their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an "outperform" rating in a research report on Wednesday, December 3rd. Weiss Ratings reissued a "buy (b-)" rating on shares of Eli Lilly and Company in a research note on Monday, December 22nd. Loop Capital set a $1,200.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, February 10th. Finally, Leerink Partners raised their target price on shares of Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the stock an "outperform" rating in a research note on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $1,221.44.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.